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Abstract
Background: To evaluate long-term clinical outcomes after treatment of complex bifurcation lesions 
with the AXXESS dedicated self-expanding biolimus A9-eluting bifurcation stent.
Methods: Between 2004 and 2013, 123 patients with complex bifurcation lesions were treated in  
a single-center with the AXXESS stent in the proximal main vessel (MV) and additional drug-eluting 
stents in branches when required. Median follow-up was 5 years. Primary endpoint was the rate of 
major adverse cardiac events (MACE). Secondary endpoints included MACE components (cardiac 
death, non-periprocedural clinical myocardial infarction [MI], target lesion revascularization [TLR] 
and definite/probable stent thrombosis [ST]) as well as all-cause death, target vessel revascularization 
(TVR) and non-TVR. 
Results: During follow-up, 11 (8.9%) patients experienced a MACE, of whom 2 (1.6%) suffered car-
diac death, 2 (1.6%) had a non-periprocedural clinical MI requiring TLR, and 7 (5.7%) underwent 
elective TLR. No definite/probable ST was observed. All-cause death occurred in 9 (7.3%) patients, TVR 
in 11 (8.9%) and non-TVR in 11 (8.9%). Patients treated for left main (LM) bifurcation lesions were 
more likely to experience MACE than non-LM bifurcation lesions (25% vs. 6.5%, p = 0.04).
Conclusions: Percutaneous revascularization of complex bifurcation lesions with the AXXESS stent 
is safe and provides excellent long-term results, especially in non-LM lesions. (Cardiol J 2018; 25, 4: 
470–478)
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Introduction
Coronary bifurcation lesions are frequently en-
countered in everyday clinical practice and account 
for 15–20% of percutaneous coronary interven-
tions (PCI) [1]. Provisional stenting with the use 
of a single drug-eluting stent (DES) is the default 
strategy. However, in the case of significant disease 
affecting both the main vessel (MV) and a large side 
branch (SB) a two-stent strategy may be required 
from the outset [2]. Nevertheless, challenges re-
main, since tubular stent design may not conform 
to bifurcation anatomy and results rely on stent 
deformation, neocarina formation and overlap-
ping strut layers provide full bifurcation coverage 
[3, 4]. Furthermore, these technical limitations 
affect optimal stent apposition and re-endothelial-
ization, which are associated with a lower proce-
dural success rate and a higher rate of long-term 
adverse cardiac events such as stent restenosis 
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and thrombosis [5–7]. Dedicated stents have there-
fore been designed to accommodate the specific 
anatomy of  bifurcation, and to preserve branch 
access and support with a single stent layer [8].
The AXXESS™ stent system (Biosensors Eu-
rope SA, Morges, Switzerland) is a conical self-ex-
panding nitinol stent, coated with a biodegradable pol-
ylactic acid (PLA) polymer eluting Biolimus A9 [9]. 
The present study sought to assess long-term 
device-oriented clinical endpoints in a large single 
center cohort of patients with complex coronary 
bifurcation lesions, including LM coronary artery 
bifurcations. 
Methods
Study population
Patients included in the study represent pooled 
experience with AXXESS at the University Hos-
pital of Leuven, Belgium, combining patients 
participating in different multicenter trials [3, 9, 
10, 11] and with others treated in routine clinical 
practice. Between 2004 and 2013, all patients in 
this center with complex bifurcation lesions un-
dergoing AXXESS stenting in the proximal MV, 
with or without additional stents in the branches, 
were included. Patients were fully informed about 
the procedure and collection of clinical data, and 
provided consent. The ethics committee of the 
indicated institution approved the study protocol 
and the latter was performed according to the 
principles outlined in the Declaration of Helsinki. 
The study population consisted of patients 
with documented stable or unstable angina or 
a positive functional study, identified for elective 
PCI of a de novo native coronary bifurcation le-
sion. Treatment with an AXXESS device was only 
considered if a two-stent bifurcation treatment 
strategy was deemed necessary from the outset, 
as per the operator’s judgement for optimal lesion 
treatment, indicating complex and diffuse disease 
and large myocardial territory at risk. Furthermore, 
eligibility required reference vessel diameter by 
visual estimate of 2.75–4.25 mm in the proximal 
MV and > 2.25 mm in the SB.  
Two operators were involved in implantation 
of the AXXESS stent, one of whom performed the 
majority of the cases (80%). 
Procedural technique
AXXESS stent characteristics and implanta-
tion procedure have been previously described 
[3, 12]. In brief, it is a self-expanding, conical-shaped 
nitinol stent with a strut thickness of 150 μm that 
elutes the highly lipophilic semisynthetic sirolimus 
analogue Biolimus A9. The drug is emulsified into 
a biodegradable PLA polymer, which is absorbed over 
6 to 9 months. The Biolimus A9 elution half-life is 21 
days, and the drug is completely eluted by 196 days 
[9]. After mandatory predilatation, AXXESS stents 
of different sizes (3 and 3.5 mm) and lengths (11 and 
14 mm) were deployed in the proximal MV, accom-
modating vessels from 2.75 mm to 3.75 mm, with 
a distal flare expanding to as much as 8 mm. A special 
(4 × 9 mm) version of the AXXESS was used in LM 
bifurcation lesions, allowing for larger diameters (up 
to 4.75 mm) and distinct bifurcation angles (flare 
end diameters of 8, 10 and 12 mm). Additional DES 
(sirolimus-eluting stents [SES] or biolimus-eluting 
stents [BES]) were implanted in case of a residual 
stenosis of > 30% in any segment of the bifurcation, 
dissection or incomplete lesion coverage. The vast 
majority of procedures were completed by sequential 
high-pressure non-compliant balloon inflations and 
final kissing balloon inflations.
Postprocedural care and follow-up
Dual antiplatelet therapy with acetylsalicylic 
acid (≥ 80 mg/day) and clopidogrel (75 mg/day) 
was administered for at least 6 months in all pa-
tients which was extended to 12 months after the 
first cases. Patients were prospectively evaluated 
clinically in the outpatient clinic or by phone at 
1-month, 1-, 3- and 5-years post-procedure.
Endpoints
The primary clinical endpoint was the rate of 
major adverse cardiac events (MACEs), defined as 
the composite of cardiac death, non-periprocedural 
clinical myocardial infarction (MI), target lesion 
revascularization (TLR) and definite/probable stent 
thrombosis (ST). Non-periprocedural clinical MI 
was defined as myocardial fraction creatine kinase 
(CK-MB) levels > 3× upper reference limit (URL) 
in combination with symptoms or electrocardio-
graphic signs of MI occurring after the periproce-
dural period. Secondary endpoints included MACE 
components as well as all-cause death, target 
vessel revascularization (TVR) and non-TVR. ST 
was classified according to the Academic Research 
Consortium [13]. Reported herein are the median 
5-year results of bifurcation lesions treated with 
AXXESS stent in the aforementioned center.
Statistical analysis
Normality of data was tested using the Kol-
mogorov-Smirnov test. Summary statistics are 
presented as mean ± standard deviation for contin-
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uous variables and as absolute numbers (percent-
ages) for categorical data. Comparisons between 
the groups of patients with and without MACEs 
were performed using the two-tailed Student t test 
for continuous variables; comparison of categorical 
variables was assessed by the c2 test. The variables 
that were found to be statistically different between 
the two groups were then fitted to univariate and 
multiple logistic regression models, in order to 
depict the best predicting factors of MACEs in the 
documented population. Estimates of odds ratios 
(ORs) and 95% confidence intervals (CIs) for each 
variable are presented. To evaluate event-free 
survival rates for each event, the Kaplan-Meier 
method was applied and 1-, 3- and 5-year event-
free survival with 95% CI were reported and sur-
vival curves constructed. Comparison of survival 
curves was performed based on a log rank test. All 
statistical analyses were performed using SPSS 
statistics software (v 20.0, IBM, Chicago, Illinois) 
and Medcalc software (version 15.2.2, Ostend, Bel-
gium). A two-sided p-value < 0.05, was considered 
statistically significant for all tests.
Results
The baseline characteristics of 123 patients in 
whom AXXESS stent implantation was intended 
are summarized in Table 1. The majority were male 
(74%) with a mean age of 64.7 years and multiple 
risk factors for ischemic heart disease. Most pa-
tients (72.4%) presented with stable angina. 
Table 1. Baseline patient characteristics.
All patients  
(n = 123)
No MACEs  
(n = 112)
MACEs  
(n = 11)
P
Demographics:
Age [years] 64.7±10.2 64.6±10.3 65.4±9.2 0.82
Male (gender) 91 (74%) 82 (73.2%) 9 (81.8%) 0.81 
Body mass index [kg/m2] 27.3 ± 3.6 27.4 ± 3.7 26.6 ± 2.6 0.53
Cardiac risk factors:
Diabetes mellitus 25 (20.3%) 23 (20.5%) 2 (18.2%) 1.00
Arterial hypertension 75 (61%) 68 (60.7%) 7 (63.6%) 1.00
Hyperlipidemia 105 (85.4%) 94 (83.9%) 11 (100%) 0.37
Smoking: 0.14
Current 27 (22%) 27 (24.1%) 0 (0%)
Former 44 (35.8%) 38 (33.9%) 6 (54.5%)
Never 52 (42.3%) 47 (42%) 5 (45.5%)
Family history of CAD 62 (50.4%) 55 (49.1%) 7 (63.6%) 0.53
Previous myocardial infarction 33 (26.8%) 32 (28.6%) 1 (9.1%) 0.29
Previous PCI 51 (41.5%) 45 (40.2%) 6 (54.5%) 0.52
Previous CABG 7 (5.7%) 5 (4.5%) 2 (18.2%) 0.12
Chronic kidney disease
Estimated GFR < 60 mL/min/1.73 m2 15 (12.2%) 14 (12.5%) 1 (9.1%) 1.00
Heart failure (> NYHA class II) 2 (1.6%) 2 (1.8%) 0 (0%) 1.00
Peripheral vascular disease 19 (15.4%) 17 (15.2%) 2 (18.2) 0.68
Previous cerebrovascular disease 9 (7.3%) 8 (7.1%) 1 (9.1%) 0.58
Clinical presentation: 0.29
Stable (angina) 89 (72.4%) 83 (74.1%) 6 (54.5%)
Unstable (angina) 30 (24.4%) 26 (23.2%) 4 (36.4%)
Silent (ischemia) 4 (3.3%) 3 (2.7%) 1 (9.1%)
Left ventricular ejection fraction [%] 60.9 ± 7.4 61 ± 7.5 60.2 ± 7.1 0.78
Values are mean ± standard deviation or number (percentage).
CABG — coronary artery bypass graft; CAD — coronary artery disease; GFR — glomerular filtration rate; MACEs — major adverse cardiac 
events consisting of cardiac death, non-periprocedural clinical myocardial infarction, target lesion revascularization and definite/probable stent 
thrombosis; NYHA — New York Heart Association; PCI — percutaneous coronary intervention
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Lesion and procedural characteristics are sum-
marized in Table 2. Most lesions (78%) were true 
bifurcation lesions (I-I-I, I-0-I and 0-I-I according to 
the Medina system) [14], most often involving the 
left anterior descending/diagonal (LAD/D) bifurcation 
(73.2%), while LM bifurcation accounted for 13% only.
Overall device success, defined as deployment 
of AXXESS without system failure or device-
related complication, was achieved in 118 (95.9%) 
patients. In 2 cases, the AXXESS stent could not 
be advanced and delivered in the bifurcation due to 
anatomical restrictions and in 1 patient the stent 
was lost in the iliac artery. Two others received an 
AXXESS stent, however in a too proximal position. 
In these cases, the target bifurcation was success-
fully treated with tubular DES only. Overall, lesion 
success (residual stenosis < 50% in any bifurcation 
segment) was obtained in 122 (99.2%) patients.
Satisfactory bifurcation treatment with an 
AXXESS stent alone was achieved in 12/118 
patients (10.2%). After AXXESS deployment, 
additional DES were implanted in distal MV 
and/or SB in 106/118 patients (89.8%). The 
distribution of these different scenarios is il-
lustrated in Figure 1. Finally, in 12/118 patients 
Figure 1. Distribution of stent implantation scenarios. 
AXXESS stents were implanted in the proximal main 
vessel (MV), with or without additional tubular drug-
eluting stents in the distal MV or side-branch (SB).
10.2% 12.7%
5.9% 71.2%
MV
SB SB
SBSB
MV
MV
MV
Table 2. Procedural characteristics.
All patients  
(n = 123)
No MACEs  
(n = 112)
MACEs  
(n = 11)
P
Target lesion (main branch):
Left main 16 (13%) 12 (10.8%) 4 (36.4%) 0.03
Left anterior descending 90 (73.2%) 86 (76.8%) 4 (36.4%)
Circumflex 13 (10.5%) 11 (9.9%) 2 (18.2%)
Right coronary artery 4 (3.3%) 3 (2.7%) 1 (9.1%)
Medina classification: 0.88
1-1-1 75 (61%) 68 (60.7%) 7 (63.6%)
1-1-0 14 (11.4%) 13 (11.6%) 1 (9.1%)
1-0-1 9 (7.3%) 8 (7.1%) 1 (9.1%)
1-0-0 7 (5.7%) 6 (5.4%) 1 (9.1%)
0-1-1 12 (9.8%) 12 (10.7%) 0 (0%)
0-1-0 1 (0.8%) 1 (0.9%) 0 (0%)
0-0-1 5 (4.1%) 4 (3.6%) 1 (9.1%)
Calcification:
Proximal main vessel 29 (23.6%) 27 (24.1%) 2 (18.2%) 1.00
Distal main vessel 29 (23.6%) 27 (24.1%) 2 (18.2%) 1.00
Side branch 23 (18.7%) 21 (18.8%) 2 (18.2%) 1.00
Total number of stents/patients 2.7 ± 07 2.7 ± 0.8 2.7 ± 0.6 0.84
Total stent length/patient [mm] 37.1 ± 14.4 37.4 ± 14.8 33.8 ± 8.7 0.25
Patients with additional stents 12 (9.8%) 12 (10.7%) 0 (0%) 0.60
Device success 118 (95.9%) 107 (95.5%) 11 (100%) 1.00
Final kissing balloon 112 (91.1%) 102 (91.1%) 10 (90.9%) 1.00
Lesion success 122 (99.2%) 111 (99.1%) 11 (100%) 1.00
Values are mean ± standard deviation or number (percentage). MACEs — major adverse cardiac events consisting cardiac death, non-peripro-
cedural clinical myocardial infarction, target lesion revascularization and definite/probable stent thrombosis
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(10.2%) further additional DES were implanted 
due to incomplete lesion coverage or proximal/distal 
edge dissections. 
All patients underwent clinical follow-up at 
1 and 3 years, and 69.1% (n = 85) could be assessed 
at 5 years. No patients were lost to follow-up. 
Median time from inclusion up to latest follow-up 
was 60 months. Kaplan-Meier event-free survival 
curves for MACE, all-cause death and TLR are 
presented in Figure 2A–C. 
Figure 2. Event-free survival curves. Kaplan-Meier event-free survival curves are presented for major adverse cardiac 
events (MACEs; A), all-cause death (B), target lesion revascularization (TLR; C); D. MACE-free survival after left main 
(LM) and non-LM intervention are compared using log rank.
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During follow-up, 11 (8.9%) patients suffered 
MACE, of whom 2 (1.6%) patients with cardiac 
death, 2 (1.6%) with non-periprocedural clinical 
MI requiring TLR, and 7 (5.7%) others underwent 
elective TLR. There was 1 sudden cardiac death 
3 years after the index procedure, accounting for 
one possible ST. All-cause death occurred in 9 (7.3%) 
and TLR was performed in 7.3% of the patients. 
Finally, TVR occurred in 11 (8.9%) and non-TVR in 
11 (8.9%) patients. A full list of events and event-
free survival are illustrated in Table 3.
Affected bifurcation segments and disease 
pattern triggering TLR are shown in Figure 3. In 
most cases, restenosis was due to failure of the 
additional DES in the distal branches, while the 
AXXESS segment was rarely involved. Patients 
treated for LM bifurcation lesions were more likely 
to experience MACE when compared with non-LM 
bifurcation lesions (25% vs. 6.5%, p = 0.04). LM bi-
furcation lesions were also an independent predic-
tor for TLR (HR 5.36, 95% CI 1.4–19.9, p = 0.02). 
Kaplan-Meier event-free survival curves for LM 
vs. non-LM bifurcation lesions are presented in 
Figure 2D. Furthermore, stent length of  MV, SB 
or total bifurcation stent length did not appear to 
affect MACE rate (data not shown).
Discussion
The present study assessed long-term clini-
cal outcomes after percutaneous revascularization 
of complex coronary bifurcation lesions with the 
AXXESS stent, a second generation DES spe-
cifically designed for bifurcation lesions. In this 
large cohort of patients with predominantly true 
bifurcation lesions, highly successful AXXESS 
implantation and accurate stent positioning, with 
or without the use of additional DES in the distal 
branches, resulted in acute lesion success in all but 
1 patient. Five-year clinical follow-up confirmed 
favorable outcomes, with single digit MACE rates 
(8.9%), cardiac death-, MI- and TLR rates as low as 
1.6%, 1.6% and 7.3%, respectively, and no definite/ 
/probable ST. While most patients were treated 
for lesions in LAD/D bifurcation, a small number 
of patients undergoing treatment of LM bifurca-
Figure 3. Distribution of restenosis triggering target le-
sion revascularization (TLR). Among 5 restenoses lead-
ing to TLR in non-left main (LM) bifurcations (left panel), 
one was located at the proximal edge of the AXXESS 
stent, and 4 affected the ostium of the branches (twice 
the distal main vessel [MV] and twice the side-branch 
[SB]). In LM bifurcations, restenosis at the ostium of the 
circumflex artery led to TLR in 4 cases; DMV — distal 
main vessel; LAD — left anterior descending; LCx — 
circumflex; PMV — proximal main vessel.
Non-left main
(n = 107)
PMV
Left main
(n = 16)
LM
LCx
LAD
SBDMV
AXXESS proximal edge:  
n = 1 (0.9%)
DMV ostium:
n = 2 (1.9%) SB ostium:
n = 2 (1.9%)
LCx ostium:
n = 4 (25%)
Table 3. Event-free survival during follow-up.
All patients  
(n = 123)
1-year  
(%)
3-years  
(%)
5-years  
(%)
Non-periprocedural MI 2 (1.6%)
All cause mortality: 9 (7.3%) 98.3 (95.9–99.9) 95.6 (91.9–99.3) 90.9 (85.2–96.6)
Cardiac death 2 (1.6%)
Non-cardiac death 7 (5.7%)
Definite/probable ST 0 
Target lesion revascularization 9 (7.3%) 94.9 (91–98.8) 94.9 (91–98.8) 91 (85.3–96.7)
Target vessel revascularization 11 (8.9%)
Non-target vessel revascularization 11 (8.9%) 94.9 (91–98.8) 90.2 (84.7–95.7) 90.2 (84.7–95.7)
MACEs 11 (8.9%) 94 (89.7–98.3) 93.1 (88.4–97.8) 89.3 (83.2–95.4)
Values are number (percentage). Event free survival data represent percentages and in parentheses 95% confidence intervals for the most 
important endpoints. MACE — major adverse cardiac events consisting cardiac death, non-periprocedural clinical myocardial infarction, target 
lesion revascularization and definite/probable stent thrombosis; MI — myocardial infarction; ST — stent trombosis
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tion were 4 times more likely to suffer an MI and 
5 times more likely to undergo TLR during follow-up.
By design, dedicated bifurcation devices offer 
solutions against the limitations of tubular stents 
by conforming to bifurcation anatomy and avoid-
ing stent deformation and overlap. Theoretically, 
they represent a valid alternative to the ongoing 
controversy of single versus double tubular stent 
strategies to be used in a bifurcation scenario 
[15–17]. However, implantation of dedicated bi-
furcation stents is technically demanding and the 
learning curve relating to patient/lesion selection 
and technical implementation, both hamper break-
through of the technique in daily practice as well as 
evaluation of its true value. Additionally, the widely 
used Medina bifurcation classification does not 
take into account calcification or bifurcation angle, 
which preferably should remain < 70° with the 
AXXESS device, making patient/lesion selection 
less straightforward. Moreover, brilliant dedicated 
stent concepts struggle with limitations inherent 
to the smaller scale and the often heterogeneous 
character of initial clinical experiences, hereby 
reinforcing the unfavorable impact of the learning 
curve. Finally, niche products have a hard time 
competing with workhorse products in following 
the pace of innovation.
The present report offers solid and long-term 
data in a sizeable group of patients with complex 
bifurcation disease treated with the AXXESS stent 
over a period of 10 years. The initial experience 
was gathered during the heydays of first generation 
sirolimus and paclitaxel-eluting products, reinforc-
ing the innovative value of this dedicated device 
in terms of bioresorbable polymer coating and 
alternative limus-elution. While the design of the 
AXXESS has not changed over time, its modular 
concept allows for combinations with the latest 
generation DES, or even fully bioresorbable scaf-
folds [18], while luminal gain at the level of proxi-
mal MV remains unprecedented [3]. The strength 
of the present registry is in the dedication of 
a single team in the treatment of complex bifurcation 
lesions with a dedicated device, completeness of 
clinical follow-up and favorable long-term results.
In this non-randomized study of a dedicated 
bifurcation device, there was a deliberate choice 
to focus on a device-oriented composite of cardiac 
death, MI and TLR as a MACE endpoint, in order 
to reflect long-term clinical device performance. 
It was decided not to include periprocedural MI in 
the composite endpoint to avoid confusion related 
to continuously changing MI definitions throughout 
the period of inclusion. In addition, due to heteroge-
neity of troponin assays and enzymatic techniques 
during the span of the study, CK-MB was used as 
a marker of myocardial necrosis. Finally, evaluation 
of individual endpoints appears to be the most 
trustworthy method of comparing outcomes as with 
a large assortment of available bifurcation studies. 
Notwithstanding favorable outcomes with 
AXXESS in a larger multicenter experience in the 
AXXESS Plus and DIVERGE trial, 5-year follow-
up in the present experience resulted numeri-
cally in even lower rates of cardiac death (1.6% 
vs. 3.3%), non-periprocedural clinical MI (1.6% 
vs. 5.5%), ischemia-driven TLR (7.3% vs. 11.5%) 
and no definite/probable ST vs. 3% [19]. Of note, 
most events in this cohort occurred in patients 
with LM bifurcation lesions, while disease in this 
bifurcation segment was an exclusion criterion in 
the aforementioned multicenter trials.
The present results also compare favorably 
with patients treated with tubular BES in bifurca-
tion segments in the all-comers LEADERS trial, 
using an identical polymer and drug concept as in 
AXXESS, and where clearly higher rates of cardiac 
death (9.3%), TLR (12%) and definite/probable ST 
(3.1%) were reported at 5 years [20]. Similarly, 
AXXESS in the present experience proved to be as 
safe and efficacious as later-generation thin-strut 
everolimus-eluting stents in the PLATINUM study 
treating non-bifurcation lesions, with similar rates 
of cardiac death (3.1%), TLR (5.7%) and definite/ 
/probable ST (0.8%) at 5 years [21].
Among studies specifically designed to elu-
cidate the controversy on single vs. double DES 
approach in bifurcation scenarios, pooled results of 
the NORDIC I and BBC ONE studies showed an 
all-cause death rate at 5 years of 6.2%, within the 
range of what is reported herein with AXXESS [22]. 
More specifically, in NORDIC I, even in the single 
stent group, a numerically higher rate of cardiac 
death (2.5%), non-periprocedural MI (4%), TLR 
(11.3%) and definite ST (3.0%) was seen [23]. Of 
note, these studies utilized first generation SES 
and paclitaxel-eluting stent, as was the case in the 
majority of cases in the present AXXESS experi-
ence, whenever additional DES were considered 
appropriate. In contrast, the present experience 
included more true bifurcation lesions and a sig-
nificantly longer cumulative stent length.
In addition, in the present study and within 
limitations of clinical follow-up, it was undertaken 
to elucidate modes of device failure and found that 
it rarely involved the AXXESS segment. Only 
1 patient had a TLR related with proximal edge 
restenosis of the AXXESS. All other TLRs oc-
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curred in the ostial branch segments where DES 
were used to cover the bifurcation, the majority of 
which were first generation DES (68.5%, cypher 
SES), which may have influenced the restenosis 
process. The low rates of cardiac death observed 
would suggest that device failure seldom leads to 
catastrophic events. 
In the present experience with AXXESS, 
treatment of LM bifurcation appeared to be an 
independent predictor of TLR and MACE. Poten-
tial contributors to this worse outcome are early 
operator experience and distinct behaviour of the 
AXXESS stent in a different anatomic environment. 
Indeed, most LM treatments took place at the 
early stage of present experience, and most events 
were concentrated in the initial AXXESS cohort 
(data not shown). In contrast, it remains unclear 
to what extent specific anatomy of LM bifurcation 
with wider angles and near-orthogonal take-off of 
the circumflex contributed to higher rates of target 
lesion failure with AXXESS [24]. Indeed, the spe-
cifically adapted and trumpet-shaped design of the 
LM stent, including a wider span at the distal end, 
was expected to favour LM bifurcation outcomes, 
due to its carina-sparing properties, the avoidance 
of neocarina formation and extensive double stent 
layers, and its conformance to bifurcation anatomy. 
However, despite its specific wide-angle design, 
close apposition of the stent to the vessel at the 
ostium of the circumflex artery may have been 
insufficient, as has been seen with more traditional 
double stent approaches in the complex three-
dimensional structure of the LM [25]. Conceptu-
ally, though, a modular approach of LM bifurcation 
reconstruction remains attractive, and is probably 
one of the few settings in which operators are 
inclined to use a multiple stent strategy, provided 
normal anatomy and flow can be restored. Of note, 
further development and marketing of the specific 
LM AXXESS has currently been abandoned.
Limitations of the study
The present study has several limitations. 
Sample size of this single center experience re-
mains relatively limited in assessing clinical out-
comes, especially in the LM group. Secondly, most 
DES used in conjunction with AXXESS during 
a long inclusion period no longer represent con-
temporary PCI practice. However, while some 
of these DES may have negatively influenced 
overall outcome results, early implementation of 
second generation DES technology with AXXESS 
proved to remain a valid option for bifurcation PCI. 
Finally, no formal comparisons with other bifurca-
tion techniques were performed in this study, but 
recent evidence revealed the value of AXXESS 
as compared with a culotte technique with latest 
generation DES [3].
Conclusions
The results of this study suggest that per-
cutaneous revascularization of complex coronary 
bifurcation lesions with dedicated AXXESS bifurca-
tion stent, with or without additional DES in the 
branches, provides a safe and attractive modular 
reconstruction of the bifurcation with excellent 
5-year results in terms of survival and MACE. 
The AXXESS stent can especially be considered 
in large non-LM bifurcations, mainly involving the 
LAD/D anatomy, with an appropriate angle when 
more than a provisional approach is anticipated.
Conflict of interest: None declared
References
1. Stankovic G, Lassen JF, Hildick-Smith D, et al. The EuroInter-
vention coronary bifurcation treatment supplement. EuroInt-
ervention. 2015; 11 Suppl V: V9–11, doi: 10.4244/EIJV11SVA2, 
indexed in Pubmed: 25983181.
2. Behan MW, Holm NR, Curzen NP, et al. Simple or complex 
stenting for bifurcation coronary lesions: a patient-level pooled-
analysis of the Nordic Bifurcation Study and the British Bifurca-
tion Coronary Study. Circ Cardiovasc Interv. 2011; 4(1): 57–64, 
doi:  10.1161/CIRCINTERVENTIONS.110.958512, indexed in 
Pubmed: 21205942.
3. Dubois C, Bennett J, Dens J, et al. COmplex coronary Bifurcation 
lesions: RAndomized comparison of a strategy using a dedicated 
self-expanding biolimus-eluting stent versus a culotte strategy 
using everolimus-eluting stents: primary results of the COBRA 
trial. EuroIntervention. 2016; 11(13): 1457–1467, doi: 10.4244/
EIJY15M05_02, indexed in Pubmed: 25947278.
4. Iakovou I, Ge L, Colombo A. Contemporary stent treatment of 
coronary bifurcations. J Am Coll Cardiol. 2005; 46(8): 1446–1455, 
doi: 10.1016/j.jacc.2005.05.080, indexed in Pubmed: 16226167.
5. Farb A, Burke AP, Kolodgie FD, et al. Pathological mechanisms of 
fatal late coronary stent thrombosis in humans. Circulation. 2003; 
108(14): 1701–1706, doi: 10.1161/01.CIR.0000091115.05480.B0, 
indexed in Pubmed: 14504181.
6. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of 
late drug-eluting stent thrombosis: strut coverage as a marker 
of endothelialization. Circulation. 2007; 115(18): 2435–2441, 
doi: 10.1161/CIRCULATIONAHA.107.693739, indexed in Pub-
med: 17438147.
7. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, 
and outcome of thrombosis after successful implantation of drug-
eluting stents. JAMA. 2005; 293(17): 2126–2130, doi: 10.1001/
jama.293.17.2126, indexed in Pubmed: 15870416.
8. Lefèvre T, Chevalier B, Louvard Y. Is there a need for dedicated 
bifurcation devices? EuroIntervention. 2010; 6 Suppl J: J123–J129, 
doi: 10.4244/EIJV6SUPJA20, indexed in Pubmed: 21930476.
478 www.cardiologyjournal.org
Cardiology Journal 2018, Vol. 25, No. 4
9. Buysschaert I, Dubois CL, Dens J, et al. Three-year clinical re-
sults of the Axxess Biolimus A9 eluting bifurcation stent system: 
the DIVERGE study. EuroIntervention. 2013; 9(5): 573–581, 
doi: 10.4244/EIJV9I5A93, indexed in Pubmed: 24058075.
10. Hasegawa T, Ako J, Koo BK, et al. Analysis of left main coro-
nary artery bifurcation lesions treated with biolimus-eluting 
DEVAX AXXESS plus nitinol self-expanding stent: intravascu-
lar ultrasound results of the AXXENT trial. Catheter Cardiovasc 
Interv. 2009; 73(1): 34–41, doi:  10.1002/ccd.21765, indexed in 
Pubmed: 19089934.
11. Miyazawa A, Ako J, Hassan A, et al. Analysis of bifurcation 
lesions treated with novel drug-eluting dedicated bifurcation 
stent system: intravascular ultrasound results of the AXXESS 
PLUS trial. Catheter Cardiovasc Interv. 2007; 70(7): 952–957, 
doi: 10.1002/ccd.21269, indexed in Pubmed: 18044777.
12. Dubois CL, Wijns W. The AXXESS™ self-expanding biolimus 
A9™ eluting stent system for coronary bifurcation lesions. Eu-
roIntervention. 2010; 6 Suppl J: J130–J134, doi: 10.4244/EIJV6S-
UPJA21, indexed in Pubmed: 21930477.
13. Cutlip DE, Windecker S, Mehran R, et al. Academic Research 
Consortium. Clinical end points in coronary stent trials: a case 
for standardized definitions. Circulation. 2007; 115(17): 2344– 
–2351, doi:  10.1161/CIRCULATIONAHA.106.685313, indexed 
in Pubmed: 17470709.
14. Medina A, Lezo JS, Pan M. A new classification of coronary bifur-
cation lesions. Rev Esp Cardiol. 2006; 59(2): 183, doi: 10.1016/
s1885-5857(06)60130-8.
15. Bennett J, Dubois C. Coronary bifurcation lesions: is less 
more? J Thorac Dis. 2016; 8(10): E1351–E1354, doi: 10.21037/
jtd.2016.10.32, indexed in Pubmed: 27867625.
16. Chen L, Fan L, Luo Y, et al. Ex vivo mono-ring technique simpli-
fies culotte stenting for treatment of true bifurcation lesions: 
Insights from bench testing and clinical application. Cardiol J. 
2016; 23(6): 673–684, doi:  10.5603/CJ.a2016.0054, indexed in 
Pubmed: 27515483.
17. Kern A, Gil RJ, Bojko K, et al. The approach to coronary bifur-
cation treatment and its outcomes in Poland: The single cent-
er experience. Cardiol J. 2017; 24(6): 589–596, doi:  10.5603/
CJ.a2017.0057, indexed in Pubmed: 28541601.
18. Bennett J, Adriaenssens T, Desmet W, et al. Complex bifurcation 
lesions: Randomized comparison of a fully bioresorbable modi-
fied t stenting strategy versus bifurcation reconstruction with 
a dedicated self-expanding stent in combination with bioresorb-
able scaffolds, an OCT study: Rationale and design of the CO-
BRA II trial. Catheter Cardiovasc Interv. 2016; 88(6): 843–853, 
doi: 10.1002/ccd.26571, indexed in Pubmed: 27184586.
19. Verheye S, Buysschaert I, Grube E. Impact of side branch stent-
ing on five-year long-term clinical outcome with the bifurcation-
dedicated Axxess Biolimus A9-eluting stent system. EuroInt-
ervention. 2015; 11(8): 860–867, doi:  10.4244/EIJV11I8A176, 
indexed in Pubmed: 26696454.
20. Grundeken MJ, Wykrzykowska JJ, Ishibashi Y, et al. First gen-
eration versus second generation drug-eluting stents for the 
treatment of bifurcations: 5-year follow-up of the LEADERS 
all-comers randomized trial. Catheter Cardiovasc Interv. 2016; 
87(7): E248–E260, doi:  10.1002/ccd.26344, indexed in Pub-
med: 26649651.
21. Stone G, Teirstein P, Meredith I, et al. Final five-year results of 
the platinum randomized trial comparing platinum chromium 
promus element and cobalt chromium promus/xience v everoli-
mus-eluting stents in workhorse lesions. J Am Coll Cardiol. 
2015; 65(10): A1733, doi: 10.1016/s0735-1097(15)61733-8.
22. Behan MW, Holm NR, de Belder AJ, et al. Coronary bifurcation 
lesions treated with simple or complex stenting: 5-year sur-
vival from patient-level pooled analysis of the Nordic Bifurcation 
Study and the British Bifurcation Coronary Study. Eur Heart 
J. 2016; 37(24): 1923–1928, doi: 10.1093/eurheartj/ehw170, in-
dexed in Pubmed: 27161619.
23. Maeng M, Holm NR, Erglis A, et al. Nordic-Baltic Percutaneous 
Coronary Intervention Study Group. Long-term results after 
simple versus complex stenting of coronary artery bifurcation 
lesions: Nordic Bifurcation Study 5-year follow-up results. J Am 
Coll Cardiol. 2013; 62(1): 30–34, doi: 10.1016/j.jacc.2013.04.015, 
indexed in Pubmed: 23644088.
24. Kang SJ, Mintz GS, Kim WJ, et al. Changes in left main bifur-
cation geometry after a single-stent crossover technique: an 
intravascular ultrasound study using direct imaging of both the 
left anterior descending and the left circumflex coronary arteries 
before and after intervention. Circ Cardiovasc Interv. 2011; 4(4): 
355–361, doi: 10.1161/CIRCINTERVENTIONS.110.961045, in-
dexed in Pubmed: 21712525.
25. Murasato Y, Horiuchi M, Otsuji Y. Three-dimensional modeling 
of double-stent techniques at the left main coronary artery bifur-
cation using micro-focus X-ray computed tomography. Catheter 
Cardiovasc Interv. 2007; 70(2): 211–220, doi: 10.1002/ccd.21133, 
indexed in Pubmed: 17421017.
